Collins C Iwuji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8160246/publications.pdf

Version: 2024-02-01

		361045	344852
52	1,431	20	36
papers	citations	h-index	g-index
56	56	56	1973
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	2.1	187
2	Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002107.	3.9	135
3	Access to primary healthcare during lockdown measures for COVID-19 in rural South Africa: an interrupted time series analysis. BMJ Open, 2020, 10, e043763.	0.8	111
4	Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials, 2013, 14, 230.	0.7	105
5	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. Journal of the International AIDS Society, 2020, 23, e25455.	1.2	96
6	Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP clusterâ€randomized trial in rural South Africa. Journal of the International AIDS Society, 2016, 19, 20913.	1.2	62
7	Linkage to <scp>HIV</scp> care after homeâ€based <scp>HIV</scp> counselling and testing in subâ€Saharan Africa: a systematic review. Tropical Medicine and International Health, 2017, 22, 807-821.	1.0	50
8	Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. Clinical Infectious Diseases, 2019, 69, 207-214.	2.9	48
9	Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 39-51.	0.6	47
10	Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study. BMC Public Health, 2013, 13, 397.	1.2	42
11	Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clinical Infectious Diseases, 2017, 64, 1006-1016.	2.9	37
12	Reduction in Early Mortality on Antiretroviral Therapy for Adults in Rural South Africa Since Change in CD4+ Cell Count Eligibility Criteria. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e17-e24.	0.9	35
13	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	1.2	34
14	Universal test and treat is not associated with subâ€optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. Journal of the International AIDS Society, 2018, 21, e25112.	1.2	34
15	Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health, 2015, 15, 209.	1.2	32
16	Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clinical Infectious Diseases, 2016, 63, 548-554.	2.9	30
17	Retention in Care Trajectories of HIV-Positive Individuals Participating in a Universal Test-and-Treat Program in Rural South Africa (ANRS 12249 TasP Trial). Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 375-385.	0.9	30
18	Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2021, 224, 377-388.	1.9	29

#	Article	IF	CITATIONS
19	"It is better to die― experiences of traditional health practitioners within the HIV treatment as prevention trial communities in rural South Africa (ANRS 12249 TasP trial). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 24-32.	0.6	28
20	Community perceptions of repeat HIV-testing: experiences of the ANRS 12249 Treatment as Prevention trial in rural South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 14-23.	0.6	23
21	Protocol: Leveraging a demographic and health surveillance system for Covid-19 Surveillance in rural KwaZulu-Natal. Wellcome Open Research, 2020, 5, 109.	0.9	18
22	Clinical outcomes after firstâ€line HIV treatment failure in South Africa: the next cascade of care. HIV Medicine, 2020, 21, 457-462.	1.0	16
23	Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: a longitudinal study of a population-based cohort in Uganda. HIV Medicine, 2011, 12, 553-561.	1.0	15
24	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. Journal of Antimicrobial Chemotherapy, 2019, 74, 473-479.	1.3	15
25	Protocol: Leveraging a demographic and health surveillance system for Covid-19 Surveillance in rural KwaZulu-Natal. Wellcome Open Research, 2020, 5, 109.	0.9	15
26	Exploring linkages between drought and HIV treatment adherence in Africa: a systematic review. Lancet Planetary Health, The, 2022, 6, e359-e370.	5.1	15
27	Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90–90–90 target. PLoS Medicine, 2017, 14, e1002293.	3.9	12
28	A systematic review of antimicrobial resistance in <i>Neisseria gonorrhoeae</i> and <i>Mycoplasma genitalium</i> in sub-Saharan Africa. Journal of Antimicrobial Chemotherapy, 2022, 77, 2074-2093.	1.3	12
29	The Art of HIV Elimination: Past and Present Science. Journal of AIDS & Clinical Research, 2015, 6, .	0.5	10
30	HIV testing: the â€~front door' to the UNAIDS 90–90–90 target. Public Health Action, 2017, 7, 79-79.	0.4	10
31	Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort. Current HIV/AIDS Reports, 2020, 17, 97-108.	1.1	10
32	Diagnostic utility of urethral smears in predicting urethral chlamydia in HIV-infected men. International Journal of STD and AIDS, 2008, 19, 741-743.	0.5	9
33	Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa. PLoS ONE, 2020, 15, e0239513.	1.1	9
34	Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa. Database: the Journal of Biological Databases and Curation, 2014, 2014, bat082-bat082.	1.4	7
35	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	1.2	7
36	CD4+ T-Cell Count at Antiretroviral Therapy Initiation in the "Treat-All―Era in Rural South Africa: An Interrupted Time Series Analysis. Clinical Infectious Diseases, 2022, 74, 1350-1359.	2.9	7

#	Article	IF	CITATIONS
37	A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naÃ-ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial. BMC Infectious Diseases, 2020, 20, 524.	1.3	6
38	Early ART Initiation Improves HIV Status Disclosure and Social Support in People Living with HIV, Linked to Care Within a Universal Test and Treat Program in Rural South Africa (ANRS 12249 TasP Trial). AIDS and Behavior, 2021, 25, 1306-1322.	1.4	6
39	Economic, social and demographic impacts of drought on treatment adherence among people living with HIV in rural South Africa: A qualitative analysis. Climate Risk Management, 2022, 36, 100423.	1.6	6
40	HIV Ascertainment through Repeat Home-based Testing in the Context of a Treatment as Prevention Trial (ANRS 12249 TasP) in Rural South Africa. AIDS Research and Human Retroviruses, 2014, 30, A287-A287.	0.5	5
41	Can I go back to work? A case of persistent SARS-CoV-2 with advanced untreated HIV infection. International Journal of STD and AIDS, 2022, 33, 209-211.	0.5	5
42	HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy. MBio, 2022, 13, e0026922.	1.8	5
43	Institutional Responses to Drought in a High HIV Prevalence Setting in Rural South Africa. International Journal of Environmental Research and Public Health, 2022, 19, 434.	1.2	4
44	Optimised electronic patient records to improve clinical monitoring of HIV-positive patients in rural South Africa (MONART trial): study protocol for a cluster-randomised trial. BMC Infectious Diseases, 2021, 21, 1266.	1.3	4
45	Early HIV treatment and survival over six years of observation in the ANRS 12249 Treatment as Prevention Trial. HIV Medicine, 2022, , .	1.0	2
46	Reply to Cohen et al. Clinical Infectious Diseases, 2016, 63, 1680-1680.	2.9	1
47	HIV assessment and testing for hospital in-patients: still a weak link in the cascade. Public Health Action, 2017, 7, 243-243.	0.4	1
48	Costs and economies of scale in repeated home-based HIV counselling and testing: Evidence from the ANRS 12249 Treatment as Prevention trial in South Africa. Social Science and Medicine, 2022, 305, 115068.	1.8	1
49	Older HIVâ€infected individuals present late and have a higher mortality: a UK clinic cohort study. Journal of the International AIDS Society, 2010, 13, P167.	1.2	0
50	Nephrotic Syndrome in Leishmaniasis. Infectious Diseases in Clinical Practice, 2011, 19, 139-141.	0.1	0
51	HIV treatment as prevention: applicable in sub-Saharan Africa?. Lancet Infectious Diseases, The, 2016, 16, 754-755.	4.6	0
52	Circulating resistance to first-line HIV drug regimens. Lancet HIV, the, 2020, 7, e77-e78.	2.1	0